[Diagnosis, treatment and follow up of prostata cancer].
Prostate cancer is the most frequent diagnosed malignancy in men with an increasing incidence. In well informed men between the age of 50 and 70 years screening should be offered when requested. Not every newly diagnosed prostate cancer requires immediate treatment. Curative treatment should be offered to men with a minimal life expectancy of 10 years. In men older than 50-75 years, therefore further screening is not necessary due to a lack of a therapeutic consequence. Curative treatment options enclose as the gold standard surgical removal, i.e. open radical prostatectomy with pelvic lymph node dissection, and radio-oncologic treatments, be it percutaneous radiation therapy, brachytherapies or a combination thereof. Palliative treatment options are mainly hormonal treatment (medical or surgical androgen deprivation), local radiation, treatment with bisphosphonates, chemotherapy and surgical desobstruction of the prostate. Regular follow up allows for early detection of recurrences and an active treatment concept.
Birkhäuser
Frédéric D
FD
Urologische Universitätsklinik, Universitätsspital, Bern.
Thalmann
George N
GN
D000359:Aftercare / Q000379:methods*; D000368:Aged; D000465:Algorithms; D000726:Androgen Antagonists / Q000627:therapeutic use; D001918:Brachytherapy; D003131:Combined Modality Therapy; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000628:therapy; D010166:Palliative Care; D011183:Postoperative Complications / Q000175:diagnosis* / Q000628:therapy; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000532:radiotherapy / Q000601:surgery*; D018714:Radiotherapy, Adjuvant
D000726:Androgen Antagonists